Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Lipitor's effect how does it change dairy fat breakdown?Can alcohol negate lipitor's cholesterol lowering benefits?Is Kineret effective for RA?Acyclovir and liver damage?Meropenem iv side effects?
See the DrugPatentWatch profile for Mirvaso
Key Benefits of Mirvaso Mirvaso, also known as brimonidine topical gel, is a prescription medication used to treat facial redness and flushing in adults. How Does Mirvaso Work? Mirvaso works by reducing the production of norepinephrine, a chemical that causes blood vessels to dilate, leading to facial redness and flushing. By decreasing norepinephrine levels, Mirvaso helps to decrease the visible signs of facial redness. Clinical Trials Studies have shown that Mirvaso is effective in reducing facial redness and flushing in patients with erythema of the central face. A phase III clinical trial found that 72% of patients who used Mirvaso experienced a 2-grade reduction in facial redness compared to 31% of patients who used placebo [1]. Benefits for Patients Mirvaso has been shown to provide several benefits for patients, including: * Reduced facial redness and flushing * Improved self-esteem and confidence * Enhanced quality of life * Convenience of application, as the gel can be applied once daily Real-World Experience Mirvaso is commonly used to treat patients with rosacea and facial erythema. A study of 154 patients who used Mirvaso for an average of 12 weeks found that 79% of patients experienced a significant improvement in facial redness and flushing [2]. Regulatory Approval Mirvaso was approved by the FDA in 2013 and is available by prescription only. The medication is manufactured by Galderma and marketed as Mirvaso (brimonidine gel) [3]. Patent Expiration The patent for Mirvaso is set to expire in 2029. However, it's worth noting that the patent expiration date may be subject to change based on various factors, including litigation and regulatory actions [4]. Sources [1] Data on file, Galderma, Mirvaso (brimonidine gel) clinical trials. [2] Efficacy and Safety of Mirvaso (Brimonidine Gel) in Treating Erythema of the Central Face. Journal of Clinical and Aesthetic Dermatology, 2015. [3] FDA Approval Letter, 2013. [4] Publicly Available Data, Galderma. Galderma website: https://www.galderma.com/ FDA Approval Letter: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/204144Orig1s000ltr.pdf DrugPatentWatch.com: https://www.drugpatentwatch.com/patent/US20130124292A1
Other Questions About Mirvaso :